EGFR and head and neck squamous cell carcinoma: In the metastatic or recurrent setting, management options may also include immune checkpoint inhibitors such as pembrolizumab or the EGFR antagonist cetuximab, given the upregulation of the EGFR pathway in 80–90% of HNSCC cases [13,14,15].